Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-828P (RNA, U6 small nuclear 828, pseudogene) is a processed pseudogene derived from the highly conserved U6 small nuclear RNA gene, which encodes the U6 component of the spliceosome, a ribonucleoprotein complex essential for splicing of precursor mRNA in eukaryotic nuclei[5][3][1]. The parental U6 snRNA is a critical non-coding RNA for messenger RNA maturation via splicing, but pseudogenes like RNU6-828P are nonfunctional; they are unable to encode functional RNA or protein and are a consequence of retrotransposon activity and genome evolution[5]. These pseudogenes do not participate in cellular pathways, drug interactions, or serve as receptors, enzymes, transcription factors, or other canonical therapeutic targets. They are mainly used as evolutionary or genomic markers without roles in disease biology, pharmacology, or therapy[5][3]. Note: RNU6-828P is often listed in genomic databases as a locus, but as a pseudogene, it is not an active or valid molecular target for therapeutics, diagnostics, or experimental modulation. The genuine target is U6 small nuclear RNA, not its pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 828, pseudogene (RNU6-828P).